- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00447187
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
A Multi-center, Placebo-Controlled, Randomized, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty With LX201 Implantation in Subjects Who Are at Increased Immunological Risk
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was intended for surgical episcleral placement in the eye.
The study was a Phase 2/3, multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study of LX201 for prevention of corneal allograft rejection or graft failure following penetrating keratoplasty with LX201 implantation. Subjects were to be followed in an outpatient setting for safety and efficacy at 4-6 week intervals for 52 weeks following transplantation surgery.
After Visit 12 (Week 52), subjects in the USA and India with the implant in the study eye were to be followed for safety at least once per year for a 2-year period or until time of implant removal. For subjects in the USA and India, if the implant was removed at any time prior to the 3 year safety follow-up, the subject was to have a final safety follow up visit at 3 months post removal. In Germany, the implant was to be removed at Week 52 with a 3-month safety follow-up period after removal.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Erlangen, Alemanha, 91054
- Augenklinik, Universitat Erlangen-Nurnberg
-
Essen, Alemanha, 45122
- Cornea Bank, Universitätsklinikum Essen
-
Kiel, Alemanha, 24105
- Klinik fuer Ophthalmologie Campus Kiel
-
Muenchen, Alemanha, 80336
- Ludwig Maximilians Universität
-
München, Alemanha, 81675
- Augenklinik der Technischen Universität München
-
Wuerzburg, Alemanha, 97080
- Augenklinik Wuerzburg
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85032
- Cornea Consultants of Arizona
-
-
California
-
Loma Linda, California, Estados Unidos, 92354
- Loma Linda University Health Care
-
Los Angeles, California, Estados Unidos, 90033
- USC Doheny Eye Institute
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Bascom Palmer Eye Institute
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory Eye Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois at Chicago
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46260
- Price Vision Group
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21218
- The Eye Center at Union Memorial Hospital
-
Baltimore, Maryland, Estados Unidos, 21287
- Wilmer Eye Institute, Cornea Service
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02111
- New England Eye Center
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48105
- W.K. Kellogg Eye Center - University of Michigan
-
-
Minnesota
-
Bloomington, Minnesota, Estados Unidos, 55431
- MN Eye Consultants, P.A.
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- Tauber Eye Center
-
St. Louis, Missouri, Estados Unidos, 63141
- Ophthalmology Associates
-
-
New Jersey
-
Newark, New Jersey, Estados Unidos, 07103
- UMDNJ - New Jersey Medical School Institute of Ophthalmology and Visual Science
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Mount Sinai School of Medicine
-
New York, New York, Estados Unidos, 10003
- New York Eye and Ear Infirmary
-
Rockville Center, New York, Estados Unidos, 11570
- Ophthalmic Consultants of Long Island
-
Slingerlands, New York, Estados Unidos, 12159
- Cornea Consultants of Albany
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Duke University Eye Center
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- University Hospitals Case Medical Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75231
- Cornea Associates of Texas
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 23502
- Virginia Eye Consultants
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- Eye Associates NW
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Subjects are candidates for a corneal transplant and are at increased immunological risk for graft failure, as evidenced by one or more of the following:
- ≥ 1 quadrant deep corneal vascularization
- verifiable history of graft failure due to rejection
- position of graft is < 1 mm from the limbus
Exclusion Criteria:
- Any condition that would greatly increase the risk of non-rejection graft failure such as Stevens-Johnson syndrome, xerophthalmia or severe exposure keratitis.
- Schirmer's test ≤ 5 mm in 1 minute
- Clinical evidence of limbal stem cell deficiency
- History of or active herpes simplex virus keratitis or other acute corneal infection
- Subjects who have had > 3 failed grafts in the study eye
- Uncontrolled glaucoma as evidenced by an intraocular pressure of >21 mmHg while on maximal medical therapy
- Clinically suspected or confirmed ocular lymphoma
- Treatment with a systemic immunosuppressive regimen within the previous 30 days; systemic prednisone (or its equivalent) of ≤ 10 mg daily is, however, permitted.
- Any implantable corticosteroid-eluting device (e.g., Retisert™, Posurdex®, Medidur™, I-vation™ TA intravitreal implant)
- Subjects who periodically require high-dose systemic steroid treatment (e.g., for exacerbation of chronic obstructive pulmonary disease).
- Subjects who have received treatment with a monoclonal antibody or any other biologic therapy within the previous 90 days or alemtuzumab within the previous 12 months
- History of herpes zoster or varicella infection within 6 weeks prior to enrollment, or chicken pox exposure within 21 days before enrollment
- Seropositivity for human immunodeficiency virus (HIV)
- Previous exposure or known contraindication to administration of cyclosporine
- Recipients of a solid organ transplant
- Currently pregnant or lactating
- Active, extraocular and/or systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of active hepatitis A, B or C
- Severe anemia (hemoglobin < 6 g/dL), leukopenia (white blood cell count [WBC] < 2500 mm3), thrombocytopenia (platelet count < 80,000 mm3), polycythemia (hematocrit [Hct] > 54% [male] or Hct > 49% [female]) or clinically significant coagulopathy
- Current malignancy or a history of malignancy (within the previous 5 years) except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been treated successfully
- Active peptic ulcer disease
- Co-morbid conditions that require immunosuppression
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: LX201 implante de 0,50 polegadas
O implante LX201 continha 30% de ciclosporina A em peso e 0,50 polegada de comprimento
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Experimental: Implante LX201 de 0,75 polegadas
O implante LX201 continha 30% de ciclosporina A em peso e 0,75 polegada de comprimento
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Comparador de Placebo: Implante Placebo de 0,75 polegadas
Implante de silicone sem ciclosporina A, 0,75 polegada de comprimento
|
O placebo foi um implante de silicone de 0,75 polegada de comprimento.
Não continha ciclosporina A
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
graft rejection or graft failure
Prazo: 52 weeks
|
52 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Eddy Anglade, MD, Chief Medical Officer, Lux Biosciences, Inc.
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- LX201-01
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doenças da Córnea
-
Eye-yon MedicalConcluídoEDEMA CORNEALIsrael, Polônia
Ensaios clínicos em LX201
-
Lux Biosciences, Inc.RescindidoTransplante de Córnea | Rejeição de enxerto de córneaEstados Unidos, Alemanha